리가켐바이오

141080KOSDAQ

43.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Ligacem Bio is a biopharmaceutical company specializing in next-generation ADC (Antibody-Drug Conjugate) technology through its proprietary platform 'ConjuALL', targeting unmet medical needs in oncology. The company has secured multiple technology transfer agreements with global pharmaceutical firms, including Fosun Pharma and Janssen, and reported revenue of approximately 10.54 billion KRW in 2024. It also operates a medical supply business, contributing to its diversified revenue streams.

Number of Employees

180people

Average Salary

157.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

4.70Industry Average 1.200.0Point

3.9x industry avg (risky)

ROE

-15.82Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

18.41Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲140.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼167.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.0% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 68,700Won52-week high 213,50052-week low 61,300

1-month return0.0Point

1m -16.73% (strong drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-10-02
Neutral투자판단관련주요경영사항 (iADC 플랫폼 공동연구 및 기술도입 계약 체결)2026-09-30